Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach

Table 1 Baseline characteristics of the subgroups

Parameter	Non-HU	HU-specific medication	HU-diagnosis w/o specific medication	P-values
N (%)	1610 (81.9%)	174 (8.6%)	182 (9.3%)	–
Gender (m/f)	937/673	154/20	133/49	p < 0.001*
Age (y)	64.2 ± 8.5 [63.8;64.6]	67.7 ± 8.3 [66.7;68.8]	66.3 ± 6.9 [65.3;67.3]	p < 0.001*
BMI (kg/m²)	26.2 ± 5.0 [26.0;26.4]	29.6 ± 5.8 [28.8;30.5]	28.4 ± 5.1 [27.7;29.1]	p < 0.001*
Packyears	47.3 ± 34.8 [45.6;49.0]	53.0 ± 31.8 [48.3;57.8]	61.6 ± 44.5 [55.1;68.1]	p < 0.001*
FEV₁%predicted	52.9 ± 18.6 [52.0;53.8]	53.4 ± 17.8 [50.8;56.1]	53.5 ± 16.6 [51.1;55.9]	p = 0.886
FVC%predicted	79.5 ± 18.9 [78.6;80.4]	76.2 ± 18.2 [73.4;78.9]	78.0 ± 18.1 [75.3;80.6]	p = 0.061
6-MWD (m)	420.6 ± 106.4 [415.4;425.8]	394.0 ± 102.2 [378.7;409.3]	401.5 ± 100.3 [386.8;416.2]	p = 0.001*
Uric acid (mg/dl)	5.83 ± 1.60 [5.75;5.91]	6.22 ± 1.43 [6.00;6.43]	7.02 ± 1.78 [6.76;7.28]	p < 0.001*
GOLD 1/2/3/4	151/685/610/164	16/79/65/14	12/84/76/10	p = 0.319
GOLD A/B/C/D	188/859/25/538	15/88/2/69	15/94/5/68	p = 0.312
Exa-cat^a (low/high)	1047/563	103/71	109/73	p = 0.148

The table shows mean values and standard deviations or absolute numbers, as well as 95% confidence intervals in square brackets. Column 4 shows the p-values of comparisons between patients without the diagnosis of hyperuricemia, those with a diagnosis plus hyperuricemia-specific medication, and those with a diagnosis but no hyperuricemia-specific medication (univariate ANOVA or chi-square-tests in the case of categorical variables). Significant (p < 0.05) differences are marked with (*). ^aExa-cat indicates the exacerbation category as used in the GOLD 2017 ABCD grouping, i.e. “low” comprising the groups A and B, and “high” comprising the groups C and D

ISSN: 1465-993X